The article discusses the SPDR S&P Biotech ETF (XBI), highlighting its role in providing exposure to the biotech sector. As a passively managed ETF, it is designed to track the performance of the biotech industry, which may interest investors looking for sector-specific exposure. However, the article does not provide any new information or events that would cause a short-term price movement, resulting in a neutral impact score.